Whereas, cancer cell lines knocked down for c-MET had a slower tumor growth rate in mice, the addition of capmatinib countered the therapeutic effect of c-MET knockdown, suggesting that TME-expressing c-MET were involved in the anti-tumor response. Here, MET is linked to neoplasm.